New results suggest that DiviTum® reflects response to palbociclib
Palbociclib is a successful targeted drug from Pfizer for patients with metastatic breast cancer. The drug was launched in 2015 and is currently selling for >$2 billion per year. Currently, no biomarkers are used for prognosis and monitoring of patients treated with Palbociclib.
The study data demonstrate that thymidine kinase can be an early marker of growth inhibition in response to palbociclib.
“This study provides more understanding and knowledge of the effect of treatment with palbociclib on a cellular level and evidence that the efficacy of palbociclib is reflected with DiviTum® and is directly related to treatment effect“, says Dr Luca Malorni, Prato Hospital, Italy.
"In this pre-clinical trial, we are able to repeat the same pattern we’ve seen in clinical trials. This strengthens the hypothesis that DiviTum® is a valuable tool as a pharmacodynamic marker of CDK 4/6 inhibition. Our aim is to contribute to more personalized cancer treatment for the best possible outcome for the patient," says Anders Rylander, CEO, Biovica International AB." says Anders Rylander, CEO, Biovica International AB.